Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Genetic Variants and Phenotypic Characteristics of Patients With T2DM (GenVarT2DM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2008 by Odense University Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Danish PhD School of Molecular Metabolism
University of Southern Denmark
Information provided by:
Odense University Hospital
ClinicalTrials.gov Identifier:
NCT00760292
First received: September 25, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted

September 25, 2008
September 25, 2008
May 2008
December 2009   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Genetic Variants and Phenotypic Characteristics of Patients With T2DM
Genetic Variants and Phenotypic Characteristics of Patients With T2DM

Background: Genetic risk-markers associated with T2DM are thoroughly studied. So far, only a few genetic variants, also termed single nucleotide polymorphisms (SNP's), have been replicated in several studies and each of them gives only limited explanation for the growing incidence of T2DM. The hypothesis of the present study is that determination of combinations of genetic variants by SNP-chip technology may improve the prediction of T2DM, complications and efficacy of treatment compared to the methods previously used including genome wide association (GWA) studies. The SNP-chip/ DNA microarray makes it possible to study several SNP's association with T2DM, one by one but also in combination.

Aims: To study whether specific genetic variants, and combinations of these, 1) are present with higher prevalence in patients with T2DM than in the normal population, 2) are associated with specific diabetes-related complications and 3) the effect of the anti-diabetic treatment.

Methods: During the next three years 1000 patients with T2DM and 1000 healthy, non-diabetic persons will be included in the study, and examined by blood samples, a questionnaire and clinical evaluation, all in one visit. Initially, we will perform DNA analyses on blood samples from 372 patients included in another clinical study from our department. Description of genetics will be done by a DNA-chip with approximately 70 SNP's, which have previously been reported to be associated with T2DM.

Results and conclusions: It is expected that the result of this project can help us predicting T2DM, diabetes-related complications and individualizing treatment to the individual patient with T2DM.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:

Whole blood

Non-Probability Sample
  1. Diabetic Patients from Dept. of Endocrinology, Odense University Hospital
  2. Non-diabetic volunteers found from advertising at Odense University Hospital
Type 2 Diabetes Mellitus
Not Provided
  • 1
    Type 2 Diabetic Patients
  • 2
    Non-diabetic individuals
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
2000
April 2011
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Type 2 Diabetes Mellitus
  • > 18 years and
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00760292
034
No
Not Provided
Odense University Hospital
  • Danish PhD School of Molecular Metabolism
  • University of Southern Denmark
Not Provided
Odense University Hospital
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP